Development of anti-cancer drugs (original) (raw)
Drug development in oncology: classical cytotoxics and molecularly targeted agents
Martin Gutierrez
British Journal of Clinical Pharmacology, 2006
View PDFchevron_right
Envisioning the future of early anticancer drug development
Shahneen Sandhu
Nature Reviews Cancer, 2010
View PDFchevron_right
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents
Veronique Dieras
Targeted Oncology, 2010
View PDFchevron_right
Contemporary pre-clinical development of anticancer agents – What are the optimal preclinical models?
Maurizio D'Incalci
European Journal of Cancer, 2009
View PDFchevron_right
Phase 0 Clinical Trials in Cancer Drug Development: From FDA Guidance to Clinical Practice
Alice Chen
Molecular Interventions, 2007
View PDFchevron_right
[Trends in oncological phase I trials]
Martin Højgaard
2019
View PDFchevron_right
Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development: Figure 1
Naoko Takebe
Japanese Journal of Clinical Oncology, 2015
View PDFchevron_right
Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)
Elizabeth Eisenhauer
European Journal of Cancer, 2008
View PDFchevron_right
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
Michelle Garrett
Drug Discovery Today, 2010
View PDFchevron_right
Targeted agents: How to select the winners in preclinical and early clinical studies?
Elizabeth Eisenhauer
European Journal of Cancer, 2012
View PDFchevron_right
Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Elizabeth Eisenhauer
JNCI Journal of the National Cancer Institute, 2004
View PDFchevron_right
Speeding up the Evaluation of New Agents in Cancer
E. Eisenhauer
JNCI Journal of the National Cancer Institute, 2008
View PDFchevron_right
Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs
Hiroyuki Seimiya
Cancer science, 2016
View PDFchevron_right
Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT)
Elizabeth Eisenhauer
European Journal of Cancer, 2008
View PDFchevron_right
The role of pharmacology in anticancer drug development
Anne-Sophie Govaerts
ADMET and DMPK
View PDFchevron_right
Phase I trials of antitumour agents: fundamental concepts
Rachel Riechelmann
ecancermedicalscience, 2015
View PDFchevron_right
Phase I Clinical Trial Design in Cancer Drug Development
Elizabeth Eisenhauer
Journal of Clinical Oncology
View PDFchevron_right
Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development?
Elizabeth Eisenhauer
1999
View PDFchevron_right
Applications for oncologic drugs: a descriptive analysis of the oncologic drugs advisory committee reviews
kiet kiet
The oncologist, 2014
View PDFchevron_right
An appraisal of drug development timelines in the Era of precision oncology
Denis Jardim
Oncotarget, 2014
View PDFchevron_right
Optimizing preclinical study design in oncology research
Luke Wittenburg
Chemico-Biological Interactions, 2011
View PDFchevron_right
Analysis of Phase II Studies on Targeted Agents and Subsequent Phase III Trials: What Are the Predictors for Success?
Suely Ueda
Journal of Clinical Oncology, 2008
View PDFchevron_right
Clinical Classification of Targeted Agents Used for Anticancer Treatment
Yuichi Takiguchi
The Tohoku Journal of Experimental Medicine, 2013
View PDFchevron_right
The Design of Phase II Clinical Trials Testing Cancer Therapeutics: Consensus Recommendations from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
Daniel Sargent
Clinical Cancer Research, 2010
View PDFchevron_right
A comprehensive review on preliminary screening models for the evaluation of anti-cancer agents
Keval Raval
IP International Journal of Comprehensive and Advanced Pharmacology
View PDFchevron_right
Prospective and Retrospective Animal Model Used in the Pharmacological Screening of Anti-Cancer Drug
Shamima Ahmed
International Journal of Current Pharmaceutical Research
View PDFchevron_right
In Vitro Assessment of Antitumor Potential and Combination Effect of Classical and Molecular-targeted Anticancer Drugs
Hiroshi Sakagami
Anticancer Research, 2019
View PDFchevron_right
Clinical trials and biomarker development with molecularly targeted agents and radiotherapy
Dhani Cell
Cancer and Metastasis Reviews, 2008
View PDFchevron_right
Guidelines for clinical evaluation of anti-cancer drugs
Naomi Kiyota
2021
View PDFchevron_right
Methodology for the Development of Innovative Cancer Therapies Task Force addresses methodological issues in the clinical development of innovative cancer therapies
Elizabeth Eisenhauer
Clinical Investigation, 2012
View PDFchevron_right
Targeting targeted agents: open issues for clinical trial design
Diana Giannarelli
Journal of Experimental & Clinical Cancer Research, 2009
View PDFchevron_right
Past, present and future use of cytotoxic agents in oncology practice: A systematic review of Pubmed and ClinicalTrials.gov databases
Antonio Ghidini
Journal of Oncology Pharmacy Practice
View PDFchevron_right
ARTICLES Phase I Trial Design for Solid Tumor Studies of Targeted, Non-Cytotoxic Agents: Theory and Practice
Elizabeth Eisenhauer
2004
View PDFchevron_right
Clinical Trials in Oncology: A Comprehensive Review
Diksha Sahai
2020
View PDFchevron_right
Anticancer drug development
Felipe Ades, Dimitrios Zardavas
Current Opinion in Oncology, 2014
View PDFchevron_right